Darren Sigal is an Oncology physician affiliated with Scripps Health. OpenAlex indexes 84 publications with 4,223 citations (h-index 23); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
10710 N Torrey Pines Rd
La Jolla, CA 920371035
Telephone
858-554-5269Provider last certified this registry record 3 Nov 2025.
Clinical trials
- ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Sponsor: Abivax S.A.
- TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
Sponsor: Scripps Clinic Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year20251 payment
- Incyte CorporationProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year202517 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
61.6%Platinum-based Drug21.3%Oxaliplatin99%Cisplatin0%Carboplatin0%Part B, office-administered≥39 patientsMicrotubule Inhibitor18.7%Paclitaxel protein-bound particles94%Paclitaxel6%Part B, office-administered≥32 patients+ 6 more classes in this area
Metabolism & gastrointestinal
17.6%Substance P/Neurokinin-1 Receptor Antagonist13.1%Aprepitant100%Part B, office-administered≥63 patientsSerotonin-3 Receptor Antagonist3%Granisetron hydrochloride89%Granisetron9%Ondansetron Hcl2%Ondansetron Odt0%Part D + Part B≥152 patients+ 6 more classes in this area
Hormonal (systemic)
10.2%Somatostatin Analog10.2%Lanreotide100%Part B, office-administered≥32 patientsl-Thyroxine0%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Edsel Abud, MD, PhD
Scripps Health
Curtiss Stinis, MD
Scripps Health
Jennifer Namazy, MD
Scripps Health
Jeffrey Rakoff, MD
Scripps Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”